Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Genomic Signatures to Predict Treatment Response (AGO-Austria)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02032745
Recruitment Status : Completed
First Posted : January 10, 2014
Last Update Posted : August 4, 2020
Information provided by (Responsible Party):
Peintinger Florentia, MD, Medical University of Graz

Brief Summary:
A genomic test was developed to predict chemo-sensitivity to taxane-anthracycline-based chemotherapy as neoadjuvant treatment. The primary aim of this study is to prospectively evaluate the microarray-based, genomic test as a predictor of axillary lymph node response. Also, to determine whether the probability of achieving negative axillary nodes, is sufficiently high for patients whose breast cancer is predicted to be chemo-sensitive to support omitting axillary dissection.

Condition or disease
Breast Neoplasms

Layout table for study information
Study Type : Observational
Actual Enrollment : 277 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Study Start Date : August 2011
Actual Primary Completion Date : July 2020
Actual Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Non-responders to chemotherapy (Probability for pathological negative nodal status)
Responders to chemotherapy (Probability for pathological negative nodal status)

Primary Outcome Measures :
  1. Probability of achieving a negative axillary nodal status [ Time Frame: at time of surgery ]
    The overall rate of pathologic lymph node-negative status (pLN0) will be evaluated, including clinically lymph node-negative (cLN-) and lymph node-positive (cLN+) patients. For sample size calculation we will consider the rate of nodal conversion from clinically node-positive (cLN+) before treatment to pathologic node-negative (pLN0) after the completion of neoadjuvant chemotherapy. Patients who are clinically node positive (cLN+) will be evaluated for nodal response, i.e. conversion to pLN0 status. We assume that 30% of these patients will be predicted by the genomic predictor as responders (i.e. pLN0 status) after neoadjuvant chemotherapy, and that 70% of them will actually achieve pLN0 status. The study will be sized to have 80% power to detect observed response (pLN-negative) rates > 50% in cLN-positive patients after neoadjuvant chemotherapy at a 95% confidence level (one sided). Probability will be measured in percent.

Biospecimen Retention:   Samples With DNA
Breast cancer tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Breast cancer patients with advanced HER 2 negative breast cancer

Inclusion Criteria:

  • Clinical status of lymph nodes must be available
  • Sonographical status of lymph nodes must be available
  • Patients must consent to documentation of cancer treatment
  • Histologic diagnosis of invasive breast cancer, clinical stage T1-4, M0 (non-inflammatory T4c)
  • Patients scheduled for neoadjuvant chemotherapy
  • Treatment with a 3-weekly FEC or AC regimen (3-4 cycles) followed by 3-4 cycles of q3 weekly docetaxel or paclitaxel.
  • Local HER2 status of tumor biopsy must be negative.

Exclusion Criteria:

  • The patient has a prior history of invasive or metastatic breast cancer.
  • The patient had prior excisional biopsy of the primary invasive breast cancer.
  • The patient had prior ipsilateral sentinel axillary lymph node biopsy for breast cancer.
  • The patient cannot safely or feasibly undergo biopsy of the primary tumor.
  • The patient has a diagnosis of Stage IV (distant metastatic) breast cancer.
  • The patient has proven HER2-positive breast cancer, defined as a pathology report of amplification of the gene or 3+ score for immunohistochemical staining.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02032745

Layout table for location information
Institute of Pathology, Med. Univ. Graz
Graz, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
Layout table for additonal information
Responsible Party: Peintinger Florentia, MD, Professor, Medical University of Graz Identifier: NCT02032745    
Other Study ID Numbers: AGO-35
KLI 406 ( Other Grant/Funding Number: FWF )
First Posted: January 10, 2014    Key Record Dates
Last Update Posted: August 4, 2020
Last Verified: August 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases